BSH 2023 | Optimizing current treatment approaches in myelofibrosis
In this video, Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, discusses an educational session that was held at this year’s BSH meeting, which focused on optimizing treatment approaches in myelofibrosis (MF). Prof. Harrison comments on the importance of ruxolitinib and strategies being explored to optimize the efficacy of this agent, and further highlights the value of novel JAK inhibitors, including momelotinib, fedratinib and pacritinib. Following this, Prof. Harrison summarizes the promising long-term safety data emerging from the MOMENTUM trial (NCT04173494). This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
